Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Dendreon
 More »

  • Bayer Prostate Cancer Drug Gains FDA Approval
    Bayer HealthCare said yesterday it is weeks away from joining Algeta in bringing to the U.S. market their advanced prostate cancer drug Xofigo® (radium Ra 223 dichloride) ...
    5-16-2013
  • GEN | Biolinks
    ... Institute Delaware Economic Development Office Delaware State University Dendreon Dengue Vaccine Initiative Deutsche Industrievereinigung Biotechnologie (DIB) ...
  • Dendreon, Plaintiffs Settle Class-Action Suit for $40M
    Dendreon said today it signed off on a $40 million securities class-action settlement to ... In a statement, Dendreon and three current and former executive officers named as ...
    3-18-2013
  • Top 10 Biopharma Layoffs of 2012
    ... Pfizer took $529 million in restructuring charges during Q4 2012 for "cost-reduction and productivity initiatives." 10. Dendreon Total workforce reduction: More than 500 full-time ...
    3-15-2013
  • Rise of Cell-Based Immunotherapy
    therapeutic cancer vaccine has been approved by the U.S. FDA-this is Provenge® from Dendreon, an autologous antigen-pulsed dendritic cell-based cancer vaccine designed to ...
    3-1-2013
  • Dendreon Profits Shrink Despite Product Revenue Gain
    Dendreon today said it finished the fourth quarter of 2012 with a net loss that continued ... For all of 2012, Dendreon finished with a net loss of $393.6 million or $2.65 per share, ...
    2-25-2013
  • Top 10 Biopharma Layoffs of 2012
    occurrence, projected savings, and costs and charges attributed to the layoffs. #10. Dendreon Total workforce reduction: More than 500 full-time and contractor jobs, primarily ...
    2-15-2013
  • Troubled Dendreon Sells Off NJ Plant
    Dendreon today said it sold to Novartis its immunotherapy manufacturing facility in Morris ... a year of weaker-than-expected sales. "Dendreon continues to make progress in improving ...
    12-20-2012
  • Biotech: A Model of Creative Acquisition
    ... The next three largest U.S. public biopharmaceutical companies-Regeneron, Onyx, and Dendreon-reported total revenues over $1.2 billion in 2011, increasing 1,700% from $67 million ...
    12-1-2012
  • Getting Cancer Immunotherapeutics Approved
    It's not just the FDA standing in the way. While biologically based therapeutic cancer vaccines and other cancer immunotherapies have great promise in treating certain cancers, ...
    11-13-2012
  • Cervical Cancer Vaccine Funded
    lasting immune response at a lower dose than traditional vaccines. Secondly, unlike Dendreon, there is no need to extract patient cells, rather we just use a simple DNA or ...
    11-12-2012
  • Majority Sees BiovaxID Gaining Faster Acceptance if Approved...
    will not face the manufacturing and reimbursement issues Dendreon has had to deal with. ... production time frames are not as limited as those of Dendreon. | Alex Philippidis
    8-23-2012
  • Dendreon Restructuring to Eliminate 600 Jobs
    After reporting a slight decrease in Provegene sales, Dendreon announced a restructuring, ... Shutdown of the Morris Plains plant will result in a loss of 600 jobs. Dendreon ...
    7-31-2012
  • Tissue Engineering Revenues Rise
    ... Although "often touted as a breakthrough TE technology," stated the authors, "it does not provide any regenerative or reconstructive function to a damaged organ or tissue. Dendreon ...
    7-1-2012
  • Autologous Immunotherapy Updates at ASCO Further Define Antitumor...
    Biovest and Dendreon presented studies involving their respective vaccines in the ... Also, Dendreon reported use of its sipuleucel-T vaccine Provenge in the neoadjuvant ...
    6-1-2012

  • Journal Articles

  • Steady Advance of Stem Cell Therapies: Report from the 2011 World...
    Melanie Swan
    Rejuvenation Research
    Steady Advance of Stem Cell Therapies: Report from the 2011 World Stem Cell Summit, Pasadena, California, October 3-5 Rejuvenation Research Abstract Stem cell research and related ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll